Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.

The U.S. Centers for Medicare & Medicaid Services, or CMS, said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation ...

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle ...

Medicare, the national health program for nearly all Americans 65 and older, was created in 1965. As the program evolves, ...

Additional 15 drugs are taken by over 5 million Americans and treat cancer, type 2 diabetes, asthma, and more WASHINGTON, D.C ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

With the passage of the Inflation Reduction Act (IRA) we saw millions of insulin dependent Medicare beneficiaries receive ...

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be ...

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...